Is AstraZeneca Stock a Buy?
Sales for AstraZeneca's oncology drugs continue to soar. Lung cancer drug Tagrisso now generates close to 16% of the company's total revenue. Overall, AstraZeneca's oncology drugs delivered year-over-year sales growth of 26% in the first half of 2020.